Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Acro Biomedical (ACBM) Operating Leases (2019 - 2025)

Acro Biomedical (ACBM) has 7 years of Operating Leases data on record, last reported at $13651.0 in Q2 2025.

  • For Q2 2025, Operating Leases fell 65.66% year-over-year to $13651.0; the TTM value through Jun 2025 reached $13651.0, down 65.66%, while the annual FY2024 figure was $26898.0, 48.5% down from the prior year.
  • Operating Leases reached $13651.0 in Q2 2025 per ACBM's latest filing, down from $18009.0 in the prior quarter.
  • Across five years, Operating Leases topped out at $52233.0 in Q4 2023 and bottomed at $5888.0 in Q3 2021.
  • Average Operating Leases over 5 years is $23729.5, with a median of $20324.0 recorded in 2024.
  • Peak YoY movement for Operating Leases: skyrocketed 141.56% in 2022, then plummeted 65.66% in 2025.
  • A 5-year view of Operating Leases shows it stood at $25719.0 in 2021, then changed by 0.0% to $25719.0 in 2022, then surged by 103.09% to $52233.0 in 2023, then plummeted by 48.5% to $26898.0 in 2024, then plummeted by 49.25% to $13651.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Leases were $13651.0 in Q2 2025, $18009.0 in Q1 2025, and $26898.0 in Q4 2024.